carbamazepine has been researched along with Body Weight in 66 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)." | 9.14 | A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. ( Aleardi, M; Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Walls, S; Williams, C; Wozniak, J, 2010) |
| "A proportion of patients undergoing epilepsy surgery, and receiving carbamazepine (CBZ), experience significant elevations in CBZ plasma concentrations, some with associated CBZ toxicity." | 9.11 | Risk factors for carbamazepine elevation and toxicity following epilepsy surgery. ( Bingaman, W; Hiremath, GK; Hovinga, C; Kotagal, P; Morris, H; Nelson, D; Wyllie, E, 2005) |
| "Changes in body weight were evaluated in 349 patients from a study comparing efficacy of add-on therapy with tiagabine (TGB), carbamazepine (CBZ) or phenytoin (PHT)." | 9.09 | Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. ( Bertrand, ME; Deaton, RL; Hogan, RE; Sommerville, KW, 2000) |
| "The PPK model, using the power scaling of body weight, effectively elucidated the topiramate serum concentration profile ranging from pediatric to adult patients." | 7.85 | Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ( Ikeda, A; Ito, S; Matsubara, K; Sugimoto, M; Takeuchi, M; Yamamoto, S; Yano, I; Yonezawa, A, 2017) |
| "To prospectively evaluate the long-term impact of valproate (VPA) versus carbamazepine (CBZ) on anthropometric, hormonal, and metabolic parameters in young male patients treated for epilepsy." | 7.81 | Endocrine Effects of Valproate versus Carbamazepine in Males with Epilepsy: A Prospective Study. ( de Vries, L; Goldberg-Stern, H; Itzhaki, T; Landau, Z, 2015) |
| " This retrospective study of children with epilepsy, aged <12 years at enrollment, examined weight gain associated with valproic acid or carbamazepine monotherapy." | 7.74 | Lack of valproic acid-associated weight gain in prepubertal children. ( Baumann, RJ; Espinosa, PS; Mendiondo, MS; Robertson, WC; Salazar, JC; Yu, L, 2008) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 7.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "Carbamazepine clearance was studied in Black paediatric epilepsy patients, 90 receiving monotherapy and 17 on combination therapy." | 7.67 | Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication. ( Summers, B; Summers, RS, 1989) |
| "The effect of carbamazepine on body weight was studied in 24 patients with affective illness." | 7.67 | Effect of carbamazepine on body weight in affectively ill patients. ( Joffe, RT; Post, RM; Uhde, TW, 1986) |
| "Oral carbamazepine has been shown to have antidiuretic activity in seven out of nine patients with neurohypophyseal diabetes insipidus." | 7.65 | Treatment of diabetes insipidus with carbamazepine. ( Wales, JK, 1975) |
| " Furthermore, the proposed population pharmacokinetic model of VPA can be used to design rational dosage regimens to achieve desirable serum concentrations." | 5.42 | A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. ( Ding, J; Jiao, Z; Li, X; Lin, W; Miao, L; Wang, C; Wang, Y; Zhao, L; Zhao, Z, 2015) |
| " No clinically relevant differences were found for using body surface area or weight to explain between-patient variability, therefore the final model included the effects of body weight on apparent clearance (CL/F) and apparent volume of distribution (V/F) of MHD, and in addition, the effect of 3 concomitant anti-epileptic drugs (carbamazepine, phenobarbital and phenytoin) on CL/F of MHD." | 5.20 | Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. ( Bouillon, T; Fink, M; Hirota, T; Sugiyama, I; Suzuki, H; Yamaguchi, M, 2015) |
| "Carbamazepine clearance was not associated with body weight or any parameterization of body size nor was age or race or any marker of hepatic or renal function in community dwelling elderly patients." | 5.16 | Population pharmacokinetics of carbamazepine in elderly patients. ( Birnbaum, AK; Brundage, RC; Collins, JF; Macias, FM; Punyawudho, B; Ramsay, ER, 2012) |
| "The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy." | 5.16 | Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. ( Brzaković, BB; Martinović, ZJ; Miljković, BR; Pokrajac, MV; Prostran, MŠ; Vezmar Kovačević, SD; Vučićević, KM, 2012) |
| "The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)." | 5.14 | A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. ( Aleardi, M; Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Walls, S; Williams, C; Wozniak, J, 2010) |
| "A proportion of patients undergoing epilepsy surgery, and receiving carbamazepine (CBZ), experience significant elevations in CBZ plasma concentrations, some with associated CBZ toxicity." | 5.11 | Risk factors for carbamazepine elevation and toxicity following epilepsy surgery. ( Bingaman, W; Hiremath, GK; Hovinga, C; Kotagal, P; Morris, H; Nelson, D; Wyllie, E, 2005) |
| "Changes in body weight were evaluated in 349 patients from a study comparing efficacy of add-on therapy with tiagabine (TGB), carbamazepine (CBZ) or phenytoin (PHT)." | 5.09 | Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. ( Bertrand, ME; Deaton, RL; Hogan, RE; Sommerville, KW, 2000) |
| "The PPK model, using the power scaling of body weight, effectively elucidated the topiramate serum concentration profile ranging from pediatric to adult patients." | 3.85 | Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ( Ikeda, A; Ito, S; Matsubara, K; Sugimoto, M; Takeuchi, M; Yamamoto, S; Yano, I; Yonezawa, A, 2017) |
| "The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)." | 3.83 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016) |
| "To prospectively evaluate the long-term impact of valproate (VPA) versus carbamazepine (CBZ) on anthropometric, hormonal, and metabolic parameters in young male patients treated for epilepsy." | 3.81 | Endocrine Effects of Valproate versus Carbamazepine in Males with Epilepsy: A Prospective Study. ( de Vries, L; Goldberg-Stern, H; Itzhaki, T; Landau, Z, 2015) |
| "The study comprised 40 children and adolescents with idiopathic epilepsy on either valproate or carbamazepine." | 3.76 | Growth hormone levels in children and adolescents with epilepsy. ( Al-Badani, AK; Aly, GS; El-Khayat, HA; Mamdouh, RM; Mohamed, EI; Tomoum, HY, 2010) |
| " This retrospective study of children with epilepsy, aged <12 years at enrollment, examined weight gain associated with valproic acid or carbamazepine monotherapy." | 3.74 | Lack of valproic acid-associated weight gain in prepubertal children. ( Baumann, RJ; Espinosa, PS; Mendiondo, MS; Robertson, WC; Salazar, JC; Yu, L, 2008) |
| " The multiple peak approach has been used to evaluate the effect of age, total body weight, dose, gender and comedication (carbamazepine-induced change) on population estimates of valproic acid relative clearance." | 3.69 | Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. ( Aoyama, T; Higuchi, S; Honda, T; Ohdo, S; Yukawa, E, 1997) |
| " Since the effects of carbamazepine on substance P content are identical with previously described effects of lithium, an alteration in substance P neurotransmission may be one of the neurochemical bases of common clinical and behavioral effects of carbamazepine and lithium on affective disorders." | 3.67 | Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders. ( Mataga, N; Mitsushio, H; Takashima, M; Toru, M, 1988) |
| "Carbamazepine clearance was studied in Black paediatric epilepsy patients, 90 receiving monotherapy and 17 on combination therapy." | 3.67 | Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication. ( Summers, B; Summers, RS, 1989) |
| "The effect of carbamazepine on body weight was studied in 24 patients with affective illness." | 3.67 | Effect of carbamazepine on body weight in affectively ill patients. ( Joffe, RT; Post, RM; Uhde, TW, 1986) |
| "Oral carbamazepine has been shown to have antidiuretic activity in seven out of nine patients with neurohypophyseal diabetes insipidus." | 3.65 | Treatment of diabetes insipidus with carbamazepine. ( Wales, JK, 1975) |
| "Delavirdine is a non-nucleoside reverse transcriptase inhibitor used in combination regimens for the treatment of HIV-1 infection." | 2.71 | Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ( Dicenzo, R; DiFrancesco, R; Fischl, M; Forrest, A; Friedland, G; Morse, GD; Para, M; Pollard, R; Shelton, M; Smith, PF, 2005) |
| "Treatment with carbamazepine (CBZ) affects cholesterol concentrations, but little is known about the precise nature and underlying mechanisms of changes in lipoprotein metabolism." | 2.70 | Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. ( Berthold, HK; Brämswig, S; Kerksiek, A; Luers, C; Sudhop, T; Von Bergmann, K, 2002) |
| "Lamotrigine (LTG) is a new antiepileptic drug (AED), chemically unrelated to the drugs in current use." | 2.68 | Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. ( Jürgens, U; May, TW; Rambeck, B, 1996) |
| "To compare carbamazepine pharmacokinetic parameters between obese and lean subjects following the administration of a single 200-mg tablet." | 2.68 | Carbamazepine pharmacokinetics in obese and lean subjects. ( Berry, EM; Caraco, Y; Levy, M; Zylber-Katz, E, 1995) |
| "Carbamazepine (CBZ) is a widely used antiepileptic drug with large interindividual variability in serum concentrations." | 1.48 | Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients. ( Huang, YT; Lu, Q; Qu, J; Qu, Q; Shu, Y; Xiang, DX; Xu, P, 2018) |
| " Furthermore, the proposed population pharmacokinetic model of VPA can be used to design rational dosage regimens to achieve desirable serum concentrations." | 1.42 | A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. ( Ding, J; Jiao, Z; Li, X; Lin, W; Miao, L; Wang, C; Wang, Y; Zhao, L; Zhao, Z, 2015) |
| "ADMS rats dominantly exhibited myokymia, neuromyotonia and generalized tonic-clonic seizures." | 1.38 | Kcna1-mutant rats dominantly display myokymia, neuromyotonia and spontaneous epileptic seizures. ( Baulac, S; Ishida, S; Kaneko, S; Kuwamura, M; Mashimo, T; Nishio, T; Ohno, Y; Sakamoto, Y; Serikawa, T; Takizawa, A, 2012) |
| "The derived models describe well VPA clearance in terms of characteristics of Serbian pediatric and adult epileptic patients, offering a basis for rational individualization of VPA dosage regimens." | 1.36 | Factors influencing valproate pharmacokinetics in children and adults. ( Jankovic, S; Jankovic, SM; Milovanovic, JR, 2010) |
| "Air-puff thresholds (mechanical allodynia), pin prick responses (mechanical hyperalgesia), and spontaneous scratching behavior were examined 3 days before surgery and at 3, 7, 10, 14, 17, 21, 24, 30, and 40 days after surgery." | 1.35 | Compression of the trigeminal ganglion produces prolonged nociceptive behavior in rats. ( Ahn, DK; Bae, YC; Han, SR; Ju, JS; Kim, BC; Lee, MK; Lim, EJ; Yang, GY, 2009) |
| "There were 23 patients with convulsions, including 13 with benign convulsions, 9 with febrile seizures, and 1 with epilepsy." | 1.35 | Clinical characteristics of benign convulsions with rotavirus gastroenteritis. ( Furukawa, S; Ichiyama, T; Kajimoto, M; Matsushige, T; Motoyama, M; Shiraishi, M, 2009) |
| "To develop a population pharmacokinetic model to evaluate the effects of variety of covariates on clearance of carbamazepine (CBZ) and its main metabolite carbamazepine-10,11-epoxide (CBZE) in Chinese population." | 1.32 | Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. ( Jiao, Z; Shi, XJ; Zhao, ZG; Zhong, MK, 2004) |
| " Pharmacokinetic interactions between antiepileptic drugs represent a major complication of epilepsy treatment with polytherapy." | 1.31 | Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview. ( Yukawa, E, 2000) |
| "37 x weight (kg); Absorption rate constant = 0." | 1.31 | Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. ( Charles, B; Hooper, WD; Parke, J; Reith, DM, 2001) |
| "The individualization of carbamazepine (CBZ) dosage regimen based on estimation of pharmacokinetic (PK) parameters and measurement of serum drug concentration in epileptic patients can help to control epilepsy." | 1.31 | Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients. ( EL Desoky, ES; Kandil, MR, 2002) |
| "Carbamazepine (CBZ) has been widely used for treatment of manic states." | 1.31 | Carbamazepine suppresses methamphetamine-induced Fos expression in a regionally specific manner in the rat brain. Possible neural substrates responsible for antimanic effects of mood stabilizers. ( Fujiwara, Y; Hamamura, T; Kuroda, S; Lee, Y; Miki, M; Ohashi, K, 2000) |
| " Patients received phenobarbitone as monotherapy or in combination with either of the antiepileptic drugs carbamazepine or valproic acid." | 1.30 | Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. ( Aoyama, T; Higuchi, S; Ohdo, S; To, H; Yukawa, E, 1998) |
| "Body weight was an important determinant of carbamazepine clearance (CL) but not volume of distribution (V)." | 1.29 | Bioavailability of controlled release carbamazepine estimated by mixed effect modelling. ( Ludden, TM; Miller, R, 1993) |
| " Steady-state trough CBZ serum concentrations, CBZ dosing history, concomitant drug administration, and other data from 45 patients were collected retrospectively." | 1.28 | Postinduction carbamazepine clearance in an adult psychiatric population. ( Crismon, ML; Godley, PJ; Martin, ES, 1991) |
| " These findings should therefore be considered when defining dosage regimens or interpreting serum drug concentrations." | 1.28 | Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid. ( Aoyama, T; Higuchi, S; Hirata, K; Ieiri, I; Yamada, H, 1990) |
| "The teratogenicity of carbamazepine (CBZ) was investigated in Sprague-Dawley CD rats at doses of 0, 200, 400, and 600 mg/kg administered by gavage in corn oil on days 7-18 of gestation in a dosage volume of 2 ml/kg." | 1.28 | Teratogenicity of carbamazepine in rats. ( Acuff, KD; Minck, DR; Vorhees, CV; Weisenburger, WP, 1990) |
| " These findings suggest that the dosage of zonisamide in epileptic patients might need to be varied depending on the comedication." | 1.27 | Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ( Buchanan, RA; Friel, PN; Levy, RH; McLean, JR; Ojemann, LM; Shastri, RA; Wilensky, AJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (24.24) | 18.7374 |
| 1990's | 14 (21.21) | 18.2507 |
| 2000's | 19 (28.79) | 29.6817 |
| 2010's | 17 (25.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Lu, Q | 1 |
| Huang, YT | 1 |
| Shu, Y | 1 |
| Xu, P | 1 |
| Xiang, DX | 1 |
| Qu, Q | 1 |
| Qu, J | 1 |
| Ding, J | 1 |
| Wang, Y | 1 |
| Lin, W | 1 |
| Wang, C | 1 |
| Zhao, L | 1 |
| Li, X | 1 |
| Zhao, Z | 1 |
| Miao, L | 1 |
| Jiao, Z | 2 |
| Goldberg-Stern, H | 1 |
| Itzhaki, T | 1 |
| Landau, Z | 1 |
| de Vries, L | 1 |
| Sugiyama, I | 1 |
| Bouillon, T | 1 |
| Yamaguchi, M | 1 |
| Suzuki, H | 1 |
| Hirota, T | 1 |
| Fink, M | 1 |
| Sarangi, SC | 1 |
| Tripathi, M | 1 |
| Kakkar, AK | 1 |
| Gupta, YK | 1 |
| Takeuchi, M | 1 |
| Yano, I | 1 |
| Ito, S | 1 |
| Sugimoto, M | 1 |
| Yamamoto, S | 1 |
| Yonezawa, A | 1 |
| Ikeda, A | 1 |
| Matsubara, K | 1 |
| Espinosa, PS | 1 |
| Salazar, JC | 1 |
| Yu, L | 1 |
| Mendiondo, MS | 1 |
| Robertson, WC | 1 |
| Baumann, RJ | 1 |
| Ahn, DK | 1 |
| Lim, EJ | 1 |
| Kim, BC | 1 |
| Yang, GY | 1 |
| Lee, MK | 1 |
| Ju, JS | 1 |
| Han, SR | 1 |
| Bae, YC | 1 |
| Motoyama, M | 1 |
| Ichiyama, T | 1 |
| Matsushige, T | 1 |
| Kajimoto, M | 1 |
| Shiraishi, M | 1 |
| Furukawa, S | 1 |
| Rauchenzauner, M | 1 |
| Griesmacher, A | 1 |
| Tatarczyk, T | 1 |
| Haberlandt, E | 1 |
| Strasak, A | 1 |
| Zimmerhackl, LB | 1 |
| Falkensammer, G | 1 |
| Luef, G | 1 |
| Högler, W | 1 |
| Li, ZH | 1 |
| Zlabek, V | 1 |
| Velisek, J | 1 |
| Grabic, R | 1 |
| Machova, J | 1 |
| Randak, T | 1 |
| Joshi, G | 1 |
| Wozniak, J | 1 |
| Mick, E | 1 |
| Doyle, R | 1 |
| Hammerness, P | 1 |
| Georgiopoulos, A | 1 |
| Kotarski, M | 1 |
| Aleardi, M | 1 |
| Williams, C | 1 |
| Walls, S | 1 |
| Biederman, J | 1 |
| El-Khayat, HA | 1 |
| Aly, GS | 1 |
| Tomoum, HY | 1 |
| Mamdouh, RM | 1 |
| Al-Badani, AK | 1 |
| Mohamed, EI | 1 |
| Jankovic, SM | 1 |
| Milovanovic, JR | 1 |
| Jankovic, S | 1 |
| Cansu, A | 2 |
| Ekinci, O | 2 |
| Serdaroglu, A | 2 |
| Gürgen, SG | 1 |
| Erdogan, D | 1 |
| Coskun, ZK | 1 |
| Tunc, L | 1 |
| Cinaz, P | 1 |
| Ishida, S | 1 |
| Sakamoto, Y | 1 |
| Nishio, T | 1 |
| Baulac, S | 1 |
| Kuwamura, M | 1 |
| Ohno, Y | 1 |
| Takizawa, A | 1 |
| Kaneko, S | 1 |
| Serikawa, T | 1 |
| Mashimo, T | 1 |
| Punyawudho, B | 1 |
| Ramsay, ER | 1 |
| Brundage, RC | 1 |
| Macias, FM | 1 |
| Collins, JF | 1 |
| Birnbaum, AK | 1 |
| Brzaković, BB | 1 |
| Vezmar Kovačević, SD | 1 |
| Vučićević, KM | 1 |
| Miljković, BR | 1 |
| Martinović, ZJ | 1 |
| Pokrajac, MV | 1 |
| Prostran, MŠ | 1 |
| Christensen, HD | 1 |
| Rayburn, WF | 1 |
| Parker, KM | 1 |
| Gonzalez, CL | 1 |
| Gold, KP | 1 |
| Shi, XJ | 1 |
| Zhao, ZG | 1 |
| Zhong, MK | 1 |
| Himmerich, H | 1 |
| Koethe, D | 1 |
| Schuld, A | 1 |
| Yassouridis, A | 1 |
| Pollmächer, T | 1 |
| Smith, PF | 1 |
| Dicenzo, R | 1 |
| Forrest, A | 1 |
| Shelton, M | 1 |
| Friedland, G | 1 |
| Para, M | 1 |
| Pollard, R | 1 |
| Fischl, M | 1 |
| DiFrancesco, R | 1 |
| Morse, GD | 1 |
| Hiremath, GK | 1 |
| Kotagal, P | 1 |
| Bingaman, W | 1 |
| Hovinga, C | 1 |
| Wyllie, E | 1 |
| Morris, H | 1 |
| Nelson, D | 1 |
| Weisler, RH | 1 |
| Hirschfeld, R | 1 |
| Cutler, AJ | 1 |
| Gazda, T | 1 |
| Ketter, TA | 1 |
| Keck, PE | 1 |
| Swann, A | 1 |
| Kalali, A | 1 |
| Smith, DF | 1 |
| Leuschner, U | 1 |
| Walther, H | 1 |
| Liu, H | 2 |
| Delgado, MR | 2 |
| Miller, R | 1 |
| Ludden, TM | 1 |
| Caraco, Y | 1 |
| Zylber-Katz, E | 1 |
| Berry, EM | 1 |
| Levy, M | 1 |
| Isojärvi, JI | 1 |
| Laatikainen, TJ | 1 |
| Knip, M | 1 |
| Pakarinen, AJ | 1 |
| Juntunen, KT | 1 |
| Myllylä, VV | 1 |
| May, TW | 1 |
| Rambeck, B | 2 |
| Jürgens, U | 1 |
| Yukawa, E | 3 |
| Honda, T | 1 |
| Ohdo, S | 2 |
| Higuchi, S | 4 |
| Aoyama, T | 4 |
| Kofman, O | 1 |
| Li, PP | 1 |
| Warsh, JJ | 1 |
| To, H | 1 |
| Sudhop, T | 2 |
| Bauer, J | 1 |
| Elger, CE | 1 |
| von Bergmann, K | 2 |
| Lee, Y | 1 |
| Hamamura, T | 1 |
| Ohashi, K | 1 |
| Miki, M | 1 |
| Fujiwara, Y | 1 |
| Kuroda, S | 1 |
| Hogan, RE | 1 |
| Bertrand, ME | 1 |
| Deaton, RL | 1 |
| Sommerville, KW | 1 |
| Reith, DM | 2 |
| Appleton, DB | 1 |
| Hooper, W | 1 |
| Eadie, MJ | 1 |
| Hooper, WD | 1 |
| Parke, J | 1 |
| Charles, B | 1 |
| Brämswig, S | 1 |
| Kerksiek, A | 1 |
| Luers, C | 1 |
| Berthold, HK | 1 |
| EL Desoky, ES | 1 |
| Kandil, MR | 1 |
| Bonhomme-Faivre, L | 1 |
| Forestier, F | 1 |
| Auchère, D | 1 |
| Soursac, M | 1 |
| Orbach-Arbouys, S | 1 |
| Farinotti, R | 1 |
| Pauwels, O | 1 |
| Yamashita, H | 1 |
| Kazawa, T | 1 |
| Minatogawa, Y | 1 |
| Ebisawa, T | 1 |
| Yamauchi, T | 1 |
| Wales, JK | 1 |
| Martin, ES | 1 |
| Crismon, ML | 1 |
| Godley, PJ | 1 |
| Ichikou, N | 1 |
| Ieiri, I | 2 |
| Hirata, K | 2 |
| Yamada, H | 2 |
| Vorhees, CV | 1 |
| Acuff, KD | 1 |
| Weisenburger, WP | 1 |
| Minck, DR | 1 |
| Mitsushio, H | 1 |
| Takashima, M | 1 |
| Mataga, N | 1 |
| Toru, M | 1 |
| Hönack, D | 1 |
| Löscher, W | 1 |
| Summers, B | 1 |
| Summers, RS | 1 |
| Sucheston, ME | 1 |
| Hayes, TG | 1 |
| Eluma, FO | 1 |
| Conti, I | 1 |
| Guiso, G | 1 |
| Urso, R | 1 |
| Caccia, S | 1 |
| Joffe, RT | 1 |
| Post, RM | 1 |
| Uhde, TW | 1 |
| Ojemann, LM | 1 |
| Shastri, RA | 1 |
| Wilensky, AJ | 1 |
| Friel, PN | 1 |
| Levy, RH | 1 |
| McLean, JR | 1 |
| Buchanan, RA | 1 |
| Hudson, JI | 1 |
| Pope, HG | 1 |
| Jonas, JM | 1 |
| Yurgelun-Todd, D | 1 |
| May, T | 1 |
| Hooshmand, H | 1 |
| Meinders, AE | 1 |
| Cejka, V | 1 |
| Robertson, GL | 1 |
| Johannessen, SI | 1 |
| Strandjord, RE | 1 |
| Fichsel, H | 1 |
| Heyer, R | 1 |
2 reviews available for carbamazepine and Body Weight
| Article | Year |
|---|---|
Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bipolar Disorder; Body Weight; Capsules; Carbamazepine; Ca | 2006 |
Toxic effects of anticonvulsants: general principles.
Topics: Adrenocorticotropic Hormone; Adult; Anticonvulsants; Benzodiazepinones; Body Surface Area; Body Weig | 1974 |
13 trials available for carbamazepine and Body Weight
| Article | Year |
|---|---|
Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Topics: Administration, Oral; Adolescent; Age Factors; Anticonvulsants; Asian People; Biotransformation; Bod | 2015 |
A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Body Weight; Carb | 2010 |
Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving oxcarbazepine.
Topics: Adolescent; Anticonvulsants; Blood Glucose; Body Weight; Carbamazepine; Child; Child, Preschool; Epi | 2011 |
Population pharmacokinetics of carbamazepine in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Rel | 2012 |
Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Area Under Curve; Body Weight; Carbamazepine; Child | 2012 |
Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Body Weight; Carbamazepine; Female; Huma | 2005 |
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Topics: Adolescent; Adult; Anti-HIV Agents; Body Weight; Carbamazepine; Delavirdine; Double-Blind Method; Dr | 2005 |
Risk factors for carbamazepine elevation and toxicity following epilepsy surgery.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool | 2005 |
Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites.
Topics: Aging; Body Weight; Carbamazepine; Child; Child, Preschool; Dose-Response Relationship, Drug; Epilep | 1994 |
Carbamazepine pharmacokinetics in obese and lean subjects.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Carbamazepine; Female; Half-Life; Humans; Male; Mid | 1995 |
Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.
Topics: Adult; Age Factors; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; D | 1996 |
Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin.
Topics: Anticonvulsants; Body Weight; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Epileps | 2000 |
Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults.
Topics: Adult; Anticonvulsants; Arteriosclerosis; Body Composition; Body Weight; Carbamazepine; Cholestanol; | 2002 |
51 other studies available for carbamazepine and Body Weight
| Article | Year |
|---|---|
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Topics: Adult; Anticonvulsants; Asian People; Body Weight; Carbamazepine; Cytochrome P-450 CYP3A; Epilepsy; | 2018 |
A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool; Drug | 2015 |
Endocrine Effects of Valproate versus Carbamazepine in Males with Epilepsy: A Prospective Study.
Topics: Adolescent; Anticonvulsants; Body Height; Body Weight; Carbamazepine; Child; Epilepsy; Humans; Male; | 2015 |
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C | 2016 |
Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Body Weight; Carbamazepine; Child; Child, Pr | 2017 |
Lack of valproic acid-associated weight gain in prepubertal children.
Topics: Adolescent; Anticonvulsants; Body Height; Body Mass Index; Body Weight; Carbamazepine; Child; Child, | 2008 |
Compression of the trigeminal ganglion produces prolonged nociceptive behavior in rats.
Topics: Agar; Analgesics, Non-Narcotic; Animals; Behavior, Animal; Body Weight; Carbamazepine; Facial Pain; | 2009 |
Clinical characteristics of benign convulsions with rotavirus gastroenteritis.
Topics: Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool; Chlorides; Creatinine; Female; | 2009 |
Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children.
Topics: Anthropometry; Anticonvulsants; Body Composition; Body Height; Body Mass Index; Body Weight; Carbama | 2010 |
Physiological condition status and muscle-based biomarkers in rainbow trout (Oncorhynchus mykiss), after long-term exposure to carbamazepine.
Topics: Algorithms; Animals; Anticonvulsants; Biomarkers; Body Weight; Carbamazepine; Catalase; DNA; Dose-Re | 2010 |
Growth hormone levels in children and adolescents with epilepsy.
Topics: Adolescent; Anthropometry; Body Weight; Carbamazepine; Chi-Square Distribution; Child; Developmental | 2010 |
Factors influencing valproate pharmacokinetics in children and adults.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Pre | 2010 |
Effects of chronic treatment with valproate and oxcarbazepine on testicular development in rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Relationship, | 2011 |
Kcna1-mutant rats dominantly display myokymia, neuromyotonia and spontaneous epileptic seizures.
Topics: Animals; Antiemetics; Biophysical Phenomena; Biotinylation; Body Weight; Carbamazepine; Cells, Cultu | 2012 |
Chronic prenatal exposure to carbamazepine and perinatal outcomes of C3H/He mice.
Topics: Animals; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Female; Mice | 2004 |
Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Asian People; Body Weight; Carbamazepine; | 2004 |
Lithium and carbamazepine: effects on learned taste aversion and open field behavior in rats.
Topics: Animals; Avoidance Learning; Behavior, Animal; Body Weight; Carbamazepine; Chlorides; Lithium; Lithi | 1983 |
[Problems of therapeutic service in carbamazepine therapy].
Topics: Adult; Biotransformation; Body Weight; Carbamazepine; Child; Drug Interactions; Humans; Phenytoin | 1980 |
The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children.
Topics: Aging; Anticonvulsants; Body Weight; Carbamazepine; Child; Chromatography, High Pressure Liquid; Dru | 1994 |
Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.
Topics: Absorption; Adolescent; Adult; Biological Availability; Body Weight; Carbamazepine; Delayed-Action P | 1993 |
Obesity and endocrine disorders in women taking valproate for epilepsy.
Topics: Adult; Body Weight; Carbamazepine; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endocrine | 1996 |
Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Topics: Adolescent; Adult; Aging; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool; Drug | 1997 |
Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin.
Topics: Adenosine Diphosphate Ribose; Analysis of Variance; Animals; Body Weight; Carbamazepine; Catalysis; | 1998 |
Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool | 1998 |
Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study.
Topics: Adult; Age Factors; Ambulatory Care; Anticonvulsants; Blood Donors; Body Weight; Carbamazepine; Chol | 1999 |
Carbamazepine suppresses methamphetamine-induced Fos expression in a regionally specific manner in the rat brain. Possible neural substrates responsible for antimanic effects of mood stabilizers.
Topics: Amphetamine-Related Disorders; Animals; Antimanic Agents; Bipolar Disorder; Body Weight; Brain; Carb | 2000 |
Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview.
Topics: Adolescent; Adult; Anticonvulsants; Biomarkers; Body Weight; Carbamazepine; Child; Child, Preschool; | 2000 |
The effect of body size on the metabolic clearance of carbamazepine.
Topics: Adolescent; Anticonvulsants; Body Height; Body Weight; Carbamazepine; Child; Cross-Sectional Studies | 2000 |
Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Biological Availability; Body Height; Body Surface | 2001 |
Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Bayes Theorem; Body Weight; Carbamazepine; Egypt; Epilepsy, Toni | 2002 |
Chronic administration of verapamil, ketoconazole and carbamazepine: impact on immunological parameters.
Topics: Animals; Anticonvulsants; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2002 |
Factors contributing to carbamazepine-macrolide interactions.
Topics: Adolescent; Adult; Aged; Aging; Anti-Bacterial Agents; Anticonvulsants; Body Weight; Carbamazepine; | 2002 |
Time-course of hepatic cytochrome p450 subfamily induction by chronic carbamazepine treatment in rats.
Topics: Animals; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Body Weight; Carbamazepi | 2002 |
Treatment of diabetes insipidus with carbamazepine.
Topics: Adolescent; Adult; Arginine Vasopressin; Body Water; Body Weight; Carbamazepine; Diabetes Insipidus; | 1975 |
Postinduction carbamazepine clearance in an adult psychiatric population.
Topics: Adult; Aged; Biological Availability; Body Weight; Carbamazepine; Female; Humans; Intestinal Absorpt | 1991 |
Analysis of the factors influencing anti-epileptic drug concentrations--carbamazepine.
Topics: Aging; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Female; Huma | 1990 |
Analysis of the factors influencing anti-epileptic drug concentrations--valproic acid.
Topics: Adolescent; Adult; Aging; Aspartate Aminotransferases; Body Weight; Carbamazepine; Dose-Response Rel | 1990 |
Teratogenicity of carbamazepine in rats.
Topics: Animals; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Female; Rats; Rats, Inbred St | 1990 |
Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders.
Topics: Animals; Body Weight; Brain Chemistry; Carbamazepine; Dopamine; Dose-Response Relationship, Drug; ga | 1988 |
Amygdala-kindling as a model for chronic efficacy studies on antiepileptic drugs: experiments with carbamazepine.
Topics: Amygdala; Animals; Anticonvulsants; Body Temperature; Body Weight; Carbamazepine; Electric Stimulati | 1989 |
Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.
Topics: Biological Availability; Black People; Body Weight; Carbamazepine; Child; Child, Preschool; Drug Int | 1989 |
Relationship between ossification and body weight of the CD-1 mouse fetus exposed in utero to anticonvulsant drugs.
Topics: Animals; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Female; Fetu | 1986 |
Inhibitory and inducing effects of denzimol on carbamazepine metabolism in the rat.
Topics: Animals; Anticonvulsants; Body Weight; Carbamazepine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome | 1987 |
Effect of carbamazepine on body weight in affectively ill patients.
Topics: Adult; Bipolar Disorder; Body Weight; Carbamazepine; Depressive Disorder; Double-Blind Method; Femal | 1986 |
Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Carbamazepine; Drug Therapy, Combination; Epilepsy; | 1986 |
Treatment of anorexia nervosa with antidepressants.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents; Antidepressive Agents, Tricyclic; Body W | 1985 |
Serum concentrations of valproic acid: influence of dose and comedication.
Topics: Adolescent; Adult; Body Weight; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epileps | 1985 |
The antidiuretic action of carbamazepine in man.
Topics: Administration, Oral; Adolescent; Adult; Arginine; Body Weight; Carbamazepine; Creatine; Diabetes In | 1974 |
The concentration of carbamazepine (Tegretol R) in serum and in cerebrospinal fluid in patients with epilepsy.
Topics: Adult; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Humans; Protein Bindi | 1972 |
[Carbamazepine in the therapy of childhood epilepsy].
Topics: Adolescent; Anticonvulsants; Behavior; Body Weight; Carbamazepine; Child; Child, Preschool; Chronic | 1970 |